Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.41 |
| ▸ | PRKACG | P22612 | 3/20 | 0.41 |
| ▸ | PRKACB | P22694 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317410 | 1.00 | ROCK2 (0.45) | ROCK2ROCK1NR4A2PRKACAPRKACG | |
| SCHEMBL3313728 | 0.94 | ROCK2 (0.52) | ROCK2ROCK1CCR2 | |
| SCHEMBL3313737 | 0.94 | ROCK2 (0.52) | ROCK2ROCK1CCR2 | |
| SCHEMBL3315326 | 0.88 | ROCK2 (0.52) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL3315333 | 0.88 | ROCK2 (0.52) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL3316997 | 0.88 | ROCK2 (0.59) | ROCK2ROCK1CCR2 | |
| SCHEMBL3317003 | 0.88 | ROCK2 (0.59) | ROCK2ROCK1CCR2 | |
| SCHEMBL3314191 | 0.85 | ROCK2 (0.42) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL3314198 | 0.85 | ROCK2 (0.42) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL3315424 | 0.84 | PRKACA (0.43) | ROCK2ROCK1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| EP-2114920-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008077552-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | ROCK2 6/4885ROCK1 5/4885NR4A2 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.